1,149.15
price up icon1.57%   17.73
after-market After Hours: 1155.75 6.60 +0.57%
loading
Lilly Eli Co stock is traded at $1,149.15, with a volume of 4.44M. It is up +1.57% in the last 24 hours and up +21.16% over the past month. Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,131.42
Open:
$1159
24h Volume:
4.44M
Relative Volume:
1.42
Market Cap:
$1.02T
Revenue:
$72.25B
Net Income/Loss:
$25.28B
P/E Ratio:
41.36
EPS:
27.781
Net Cash Flow:
$10.37B
1W Performance:
+6.19%
1M Performance:
+21.16%
6M Performance:
+15.19%
1Y Performance:
+49.26%
1-Day Range:
Value
$1,143.60
$1,182.73
1-Week Range:
Value
$1,052.15
$1,182.73
52-Week Range:
Value
$623.78
$1,182.73

Lilly Eli Co Stock (LLY) Company Profile

Name
Name
Lilly Eli Co
Name
Phone
(317) 276-2000
Name
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Name
Employee
50,000
Name
Twitter
@LillyPad
Name
Next Earnings Date
2026-04-30
Name
Latest SEC Filings
Name
LLY's Discussions on Twitter

Compare LLY vs JNJ, ABBV, MRK, AZN

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
LLY icon
LLY
Lilly Eli Co
1,149.15 1.01T 72.25B 25.28B 10.37B 27.78
JNJ icon
JNJ
Johnson Johnson
232.16 560.33B 96.36B 21.04B 17.80B 8.6488
ABBV icon
ABBV
Abbvie Inc
223.07 401.47B 62.82B 3.60B 19.98B 2.0274
MRK icon
MRK
Merck Co Inc
119.52 298.33B 65.51B 8.93B 14.12B 3.5532
AZN icon
AZN
Astrazeneca Plc
181.55 288.38B 60.48B 10.40B 8.05B 3.3297

Lilly Eli Co Stock (LLY) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-17-26 Downgrade HSBC Securities Hold → Reduce
Feb-25-26 Initiated RBC Capital Mkts Outperform
Feb-20-26 Initiated Barclays Overweight
Jan-07-26 Resumed UBS Buy
Dec-16-25 Upgrade Daiwa Securities Neutral → Buy
Dec-15-25 Reiterated BofA Securities Buy
Dec-15-25 Reiterated Goldman Buy
Nov-13-25 Initiated Scotiabank Sector Outperform
Nov-10-25 Upgrade Leerink Partners Market Perform → Outperform
Oct-20-25 Reiterated BMO Capital Markets Outperform
Oct-14-25 Upgrade Erste Group Hold → Buy
Sep-17-25 Downgrade Berenberg Buy → Hold
Aug-27-25 Upgrade HSBC Securities Reduce → Hold
Aug-18-25 Downgrade Daiwa Securities Outperform → Neutral
Aug-07-25 Downgrade Leerink Partners Outperform → Market Perform
Jun-05-25 Downgrade Erste Group Buy → Hold
Apr-28-25 Downgrade HSBC Securities Buy → Reduce
Apr-22-25 Initiated Cantor Fitzgerald Overweight
Dec-10-24 Resumed BofA Securities Buy
Nov-15-24 Initiated Wolfe Research Outperform
Oct-17-24 Initiated Bernstein Outperform
Sep-13-24 Resumed Citigroup Buy
Aug-12-24 Upgrade Deutsche Bank Hold → Buy
Feb-21-24 Downgrade DZ Bank Buy → Hold
Feb-16-24 Reiterated Morgan Stanley Overweight
Dec-21-23 Downgrade Daiwa Securities Buy → Outperform
Nov-09-23 Initiated Deutsche Bank Hold
Oct-20-23 Resumed UBS Buy
Aug-09-23 Upgrade Jefferies Hold → Buy
Jul-26-23 Reiterated Citigroup Buy
Jul-14-23 Initiated HSBC Securities Buy
May-24-23 Reiterated BofA Securities Buy
May-24-23 Reiterated UBS Buy
Mar-13-23 Upgrade Wells Fargo Equal Weight → Overweight
Mar-06-23 Initiated Jefferies Hold
Feb-15-23 Downgrade Societe Generale Hold → Sell
Nov-18-22 Initiated Credit Suisse Outperform
Sep-22-22 Upgrade UBS Neutral → Buy
May-23-22 Initiated SVB Leerink Outperform
Apr-06-22 Resumed Morgan Stanley Overweight
Mar-10-22 Initiated Daiwa Securities Outperform
Jan-21-22 Upgrade DZ Bank Hold → Buy
Jan-03-22 Reiterated Bernstein Mkt Perform
Dec-17-21 Initiated Goldman Neutral
Dec-16-21 Reiterated BMO Capital Markets Outperform
Dec-16-21 Reiterated BofA Securities Buy
Dec-09-21 Resumed Wells Fargo Equal Weight
Nov-19-21 Initiated BMO Capital Markets Outperform
Oct-11-21 Upgrade Berenberg Hold → Buy
Sep-29-21 Upgrade Citigroup Neutral → Buy
Aug-05-21 Upgrade DZ Bank Hold → Buy
Jul-27-21 Resumed Truist Buy
Jun-24-21 Reiterated Cantor Fitzgerald Overweight
Jan-19-21 Upgrade Mizuho Neutral → Buy
Dec-10-20 Upgrade Wolfe Research Peer Perform → Outperform
Nov-10-20 Resumed Bernstein Mkt Perform
Sep-29-20 Initiated Berenberg Hold
Sep-03-20 Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-16-20 Upgrade Guggenheim Neutral → Buy
Apr-21-20 Downgrade UBS Buy → Neutral
Apr-09-20 Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-06-20 Initiated Mizuho Neutral
Dec-18-19 Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-17-19 Resumed BofA/Merrill Buy
May-28-19 Initiated Goldman Buy
Apr-24-19 Upgrade Edward Jones Hold → Buy
Apr-11-19 Downgrade Guggenheim Buy → Neutral
Mar-12-19 Initiated JP Morgan Overweight
Jan-23-19 Initiated UBS Buy
Nov-26-18 Downgrade Citigroup Buy → Neutral
Oct-31-18 Upgrade Credit Suisse Underperform → Neutral
Oct-09-18 Initiated Guggenheim Buy
Oct-01-18 Reiterated SunTrust Buy
Sep-26-18 Resumed JP Morgan Overweight
View All

Lilly Eli Co Stock (LLY) Latest News

pulisher
Jun 08, 2026

Why Eli Lilly (LLY) Stock Is Up Today - Yahoo Finance

Jun 08, 2026
pulisher
Jun 08, 2026

Eli Lilly's oral weight-loss drug shows major fat loss across stages of menopause in trials - Indian Pharma Post

Jun 08, 2026
pulisher
Jun 08, 2026

Eli Lilly Conspiracy Claim In Compound Drug Row Challenged - Law360

Jun 08, 2026
pulisher
Jun 08, 2026

Why Eli Lilly Stock Climbed to a New All-Time High Today - The Motley Fool

Jun 08, 2026
pulisher
Jun 08, 2026

Calmer waters for FDA; Servier , Lilly deals — a BioCentury podcast - BioCentury

Jun 08, 2026
pulisher
Jun 08, 2026

Sizing up Lilly’s dealmaking spree - BioCentury

Jun 08, 2026
pulisher
Jun 08, 2026

Pharos iBio Joins Eli Lilly’s Global AI Drug Discovery Ecosystem - 아시아경제

Jun 08, 2026
pulisher
Jun 08, 2026

Lilly Just Announced 3 Infectious Disease Acquisitions in 1 Day. Is This the Beginning of Its Post-Obesity Growth Strategy? - The Motley Fool

Jun 08, 2026
pulisher
Jun 08, 2026

Top 20 by Trading Volume | Chip stocks rebound across the board, with Intel surging over 11% after securing a major order from Google for 3 million TPUs, Marvell rising nearly 10%, and AMD gaining more than 5%; Eli Lilly and Co. pioneers a new frontier in - 富途牛牛

Jun 08, 2026
pulisher
Jun 08, 2026

Eli Lilly and Co Options Spot-On: On June 8th, 73,672 Contracts Were Traded, With 388.59K Open Interest - Moomoo

Jun 08, 2026
pulisher
Jun 08, 2026

Eli Lilly (LLY) Shares Rise After Positive Phase 3 Diabetes Drug Data - GuruFocus

Jun 08, 2026
pulisher
Jun 08, 2026

Eli Lilly (LLY) Reports Promising Results from Phase 3 Trials of Foundayo - GuruFocus

Jun 08, 2026
pulisher
Jun 08, 2026

Lilly's oral GLP-1 Foundayo delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials - Investing News Network

Jun 08, 2026
pulisher
Jun 08, 2026

Apple AI Hype Fuels Tech Stocks, Eli Lilly Gains - StartupHub.ai

Jun 08, 2026
pulisher
Jun 08, 2026

Eli Lilly stock rises as Retatrutide data boosts obesity drug lead - CryptoRank

Jun 08, 2026
pulisher
Jun 08, 2026

Eli Lilly gene-editing therapy shows promising results of reducing high cholesterol - WTHR

Jun 08, 2026
pulisher
Jun 08, 2026

A Weight-Loss Rival Just Crashed 23%. Why That's Great News for Eli Lilly and Novo Nordisk. - Yahoo Finance

Jun 08, 2026
pulisher
Jun 08, 2026

Eli Lilly and Co.'s stock surged to a record high as next-generation weight-loss drug retatrutide impressed the market with its data. - 富途牛牛

Jun 08, 2026
pulisher
Jun 08, 2026

Lilly's powerful new weight loss drug impresses while other experimental shots struggle - CNBC

Jun 08, 2026
pulisher
Jun 08, 2026

Retatrutide Boosts Eli Lilly's (LLY) Stock by Over 3% - GuruFocus

Jun 08, 2026
pulisher
Jun 08, 2026

Eli Lilly and Co Stock (LLY) Moved Up by 3.37% on Jun 8: What Signal Does It Send? - TradingKey

Jun 08, 2026
pulisher
Jun 08, 2026

Purdue board approves elevating Lilly research center - Inside INdiana Business

Jun 08, 2026
pulisher
Jun 08, 2026

Zacks Investment Ideas feature highlights: Eli Lilly and Merck - Yahoo Finance Singapore

Jun 08, 2026
pulisher
Jun 08, 2026

Global markets live: Nvidia, Eli Lilly, Marvell Tech, Saudi Aramco… - marketscreener.com

Jun 08, 2026
pulisher
Jun 08, 2026

Bernstein reiterates Eli Lilly stock rating on obesity drug data By Investing.com - Investing.com Australia

Jun 08, 2026
pulisher
Jun 08, 2026

Eli Lilly’s $12.8 billion obesity bet faces new Medicare test - thestreet.com

Jun 08, 2026
pulisher
Jun 08, 2026

Lilly shares rise on hopes that next-gen drug will extend lead in weight-loss market - Reuters

Jun 08, 2026
pulisher
Jun 08, 2026

Bernstein reiterates Eli Lilly stock rating on obesity drug data - Investing.com

Jun 08, 2026
pulisher
Jun 08, 2026

Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage - CNBC

Jun 08, 2026
pulisher
Jun 08, 2026

Truist reiterates Eli Lilly stock rating on obesity drug data By Investing.com - Investing.com Canada

Jun 08, 2026
pulisher
Jun 08, 2026

Soley Therapeutics Names Former Eli Lilly Executive Berthil Clasen Chief Business Officer - citybiz

Jun 08, 2026
pulisher
Jun 08, 2026

Eli Lilly Highlights Weight Loss Benefits For Women Across Menopausal Stages - Benzinga

Jun 08, 2026
pulisher
Jun 08, 2026

Retatrutide Shows Promising Results in Phase 3 Trial for Diabetes Treatment - GuruFocus

Jun 08, 2026
pulisher
Jun 08, 2026

Broadcom, Corning, Micron, Eli Lilly, and More Stocks That Explain Today's Market -- Barrons.com - Moomoo

Jun 08, 2026
pulisher
Jun 08, 2026

Lilly’s 30% Weight Loss Sets High Bar for Obesity Drug Race - Bloomberg

Jun 08, 2026
pulisher
Jun 08, 2026

Eli Lilly Obesity Wins Recast Retatrutide And Foundayo As Cardiometabolic Story - Yahoo Finance

Jun 08, 2026
pulisher
Jun 08, 2026

Eli Lilly stock gains after obesity drug data at conference - Investing.com

Jun 08, 2026
pulisher
Jun 08, 2026

Will Menopause Data and Coverage Wins Recast Eli Lilly’s (LLY) Obesity-Care Narrative? - simplywall.st

Jun 08, 2026
pulisher
Jun 08, 2026

Q1 Earnings Review: Branded Pharmaceuticals Stocks Led by Eli Lilly (NYSE:LLY) - Yahoo Finance

Jun 08, 2026
pulisher
Jun 08, 2026

Why is Eli Lilly stock rallying today? By Investing.com - Investing.com Australia

Jun 08, 2026
pulisher
Jun 08, 2026

Roche bets $700M upfront on Nurix’s late-phase BTK degrader to tee up Lilly showdown - Fierce Biotech

Jun 08, 2026
pulisher
Jun 08, 2026

Eli Lilly Could Become The World's Top AI Firm? Jordi Visser Has Reasons To Believe Mounjaro Maker Could - Benzinga

Jun 08, 2026
pulisher
Jun 08, 2026

Eli Lilly Hits $1.01 Trillion Valuation as New Obesity Drug Data Reinforces GLP-1 Dominance - FXLeaders

Jun 08, 2026
pulisher
Jun 08, 2026

Why Did Solidion, Eli Lilly, Citigroup Stocks Hit 52-Week Highs Last Week? - Yahoo Finance

Jun 08, 2026
pulisher
Jun 07, 2026

Eli Lilly (LLY) Reports Promising Weight Loss Results for Women in Menopause - GuruFocus

Jun 07, 2026
pulisher
Jun 07, 2026

Eli Lilly (LLY) Reports Promising Weight Loss Data for Foundayo in Women - GuruFocus

Jun 07, 2026
pulisher
Jun 07, 2026

Lilly's Foundayo , the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause - Investing News Network

Jun 07, 2026
pulisher
Jun 07, 2026

Could NYSE Composite Spotlight Grow as Lilly Expands Obesity Coverage? - Kalkine Media

Jun 07, 2026
pulisher
Jun 07, 2026

Eli Lilly oral drug linked to 30.4 lbs loss for women, no food timing rules - Stock Titan

Jun 07, 2026
pulisher
Jun 07, 2026

Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause - PR Newswire

Jun 07, 2026
pulisher
Jun 07, 2026

Eli Lilly's $3.8 Billion Vaccine Bets: Here's the Big Story Many Investors Are Missing - AOL.com

Jun 07, 2026

Lilly Eli Co Stock (LLY) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
JNJ JNJ
$232.16
price down icon 0.26%
$223.07
price down icon 1.83%
MRK MRK
$119.52
price down icon 1.05%
AZN AZN
$181.55
price down icon 2.37%
NVS NVS
$146.42
price down icon 1.84%
Cap:     |  Volume (24h):